Lazard Asset Management
MRSN

Lazard Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Lazard Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-484
Closed -$17K – 2472
2024
Q4 		$17K Buy
+484
New +$25K ﹤0.01% 2081
2023
Q2 		– Sell
-433
Closed -$44K – 2453
2023
Q1 		$44K Buy
+433
New +$60.8K ﹤0.01% 1844

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Lazard Asset Management's MRSN Position: Q1 2025 in Review

Lazard Asset Management sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 484 shares — an estimated $17K sold.

Lazard Asset Management first reported a position in MRSN in Q1 2023 and held it in 2 quarters. The position peaked at $44K in Q1 2023. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Lazard Asset Management reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 484 Mersana Therapeutics shares in Q1 2025, an estimated $17K.
  • Lazard Asset Management first reported a position in Mersana Therapeutics in Q1 2023 and held it in 2 quarters.
  • Lazard Asset Management's Mersana Therapeutics position peaked at $44K in Q1 2023.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.